Stockscreener 앱 받기
61.30
1.13%
-0.70
시간 외 거래:
60.90
-0.40
-0.65%
전일 마감가:
$62.00
열려 있는:
$62.24
하루 거래량:
303.84K
Relative Volume:
0.37
시가총액:
$2.92B
수익:
-
순이익/손실:
$-86.97M
주가수익비율:
-25.34
EPS:
-2.4189
순현금흐름:
$-81.88M
1주 성능:
+1.93%
1개월 성능:
+17.19%
6개월 성능:
+69.95%
1년 성능:
+320.73%
1일 변동 폭
$60.40
$64.78
1주일 범위
$57.23
$66.66
52주 변동 폭
$9.63
$66.66
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
61.30 | 2.95B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-12-04 | 개시 | Goldman | Sell |
| 2025-11-04 | 개시 | TD Cowen | Buy |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-08-15 | 재개 | Jefferies | Buy |
| 2025-08-05 | 개시 | Mizuho | Outperform |
| 2025-07-16 | 개시 | Oppenheimer | Outperform |
| 2025-04-10 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | JP Morgan | Overweight |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Stifel | Buy |
모두보기
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
MBX Biosciences Inc (MBX) Institutional Confidence - TradingKey
MBX Biosciences, Inc. $MBX is Orbimed Advisors LLC's 10th Largest Position - MarketBeat
MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MBX Biosciences Market Sentiment - Benzinga España
MBX Biosciences Inc (MBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MBX Biosciences Inc (MBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBX Biosciences, Inc. Revenue Breakdown – NASDAQ:MBX - TradingView
MBX Biosciences Inc (MBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MBX|MBX Biosciences Inc|Price:62.000|Chg%:-1.570 - TradingKey
TradingKey - TradingKey
MBX Biosciences Inc (MBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Affinity Asset Advisors LLC Reduces Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sets New 12-Month HighHere's Why - MarketBeat
MBX Biosciences stock hits all-time high at 66.66 USD - Investing.com
MBX Biosciences stock hits all-time high at 66.66 USD By Investing.com - Investing.com Canada
MBX Biosciences (NASDAQ:MBX) Shares Up 6.5%Here's Why - MarketBeat
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MBX 8-K及美國證券交易委員會申報文件 - Yahoo 財經
MBX Biosciences (NASDAQ:MBX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
MBX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
MBX Biosciences (NASDAQ:MBX) Trading 5.1% HigherWhat's Next? - MarketBeat
Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge? - Sahm
Attovia Therapeutics appoints John Smither to board By Investing.com - Investing.com Australia
Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating - Moomoo
Attovia Therapeutics appoints John Smither to board - Investing.com UK
Attovia Appoints New Independent Director - Intellectia AI
How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment Narrative - Sahm
Goelzer Investment Management, Inc.'s MBX Biosciences Inc(MBX) Holding History - GuruFocus
FMR LLC's Strategic Acquisition of MBX Biosciences Inc Shares - GuruFocus
MBX Biosciences Announces CEO Transition and Leadership Updates - The Globe and Mail
Carmel-based MBX Biosciences makes leadership changes - Inside INdiana Business
MBX Biosciences (NASDAQ:MBX) Shares Gap DownShould You Sell? - MarketBeat
Stocks to Watch: Lulu's Fashion Lounge Holdings, MBX Biosciences, Rithm Property Trust - Moomoo
MBX Biosciences Appoints New CEO and CFO: Leadership Changes Announced in July 2026 8-K Filing - Minichart
MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth - TradingView
MBX Biosciences names Steve Hoerter as CEO, Kent Hawryluk steps down - Investing.com UK
MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO - MSN
MBX Biosciences Appoints Steve Hoerter as CEO; Kent Hawryluk Steps Down - Moomoo
MBX Biosciences (Nasdaq: MBX) names new CEO and CFO, sets pay and equity - Stock Titan
MBX Biosciences Sinks as Sudden CEO Shake-Up Alarms Wall Street - TipRanks
MBX Biosciences stock falls on CEO and CFO leadership changes By Investing.com - Investing.com Nigeria
MBX Biosciences stock falls on CEO and CFO leadership changes - Investing.com India
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth - The Manila Times
MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026 - marketscreener.com
Enterprise value to EBIT forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
Candriam S.C.A. Purchases New Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
Price to sales forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
MBX Biosciences (NASDAQ:MBX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
MBX Biosciences (NASDAQ:MBX) Trading Down 6.9%Time to Sell? - MarketBeat
MBX Biosciences: From $10 To $64 As Hypoparathyroidism Drug Advances - RTTNews
Mbx Biosciences Inc (MBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):